BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 7137099)

  • 21. [Estrogen and progesterone receptors of primary breast carcinoma and their axillary lymph node metastases--immunohistochemical investigations of routine formalin-fixed paraffin-embedded tissue].
    Schulze MH; Buchmann J
    Zentralbl Gynakol; 2000; 122(2):92-5. PubMed ID: 10721188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Estrogen receptor-negative, progesterone receptor-positive breast carcinoma: poor clinical outcome.
    Keshgegian AA; Cnaan A
    Arch Pathol Lab Med; 1996 Oct; 120(10):970-3. PubMed ID: 12046611
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women.
    Missmer SA; Eliassen AH; Barbieri RL; Hankinson SE
    J Natl Cancer Inst; 2004 Dec; 96(24):1856-65. PubMed ID: 15601642
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Estrogen and progesterone receptors in breast cancer: comparison between enzyme immunoassay and computer-assisted image analysis of immunocytochemical assay.
    Cavaliere A; Bucciarelli E; Sidoni A; Bianchi G; Pietropaoli N; Ludovini V; Vitali R
    Cytometry; 1996 Sep; 26(3):204-8. PubMed ID: 8889392
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hormone receptor status of a contralateral breast cancer is independent of the receptor status of the first primary in patients not receiving adjuvant tamoxifen.
    Arpino G; Weiss HL; Clark GM; Hilsenbeck SG; Osborne CK
    J Clin Oncol; 2005 Jul; 23(21):4687-94. PubMed ID: 15837971
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization.
    Basu S; Chen W; Tchou J; Mavi A; Cermik T; Czerniecki B; Schnall M; Alavi A
    Cancer; 2008 Mar; 112(5):995-1000. PubMed ID: 18098228
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Biochemical correlates of morphologic differentiation in human breast cancer.
    Silva JS; Cox CE; Wells SA; Paull D; Dilley WG; McCarty KS; Fetter BF; Glaubitz LC; McCarty KS
    Surgery; 1982 Sep; 92(3):443-9. PubMed ID: 7202259
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.
    Huang HJ; Neven P; Drijkoningen M; Paridaens R; Wildiers H; Van Limbergen E; Berteloot P; Amant F; Christiaens MR; Vergote I
    Breast Cancer Res Treat; 2005 May; 91(1):81-7. PubMed ID: 15868434
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quantitative analysis of estrogen receptor-alpha and -beta messenger RNA expression in breast carcinoma by real-time polymerase chain reaction.
    Iwao K; Miyoshi Y; Egawa C; Ikeda N; Tsukamoto F; Noguchi S
    Cancer; 2000 Oct; 89(8):1732-8. PubMed ID: 11042568
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The stability of estrogen and progesterone receptor expression on breast carcinoma cells stored as PreservCyt suspensions and as ThinPrep slides.
    Tabbara SO; Sidawy MK; Frost AR; Brosky KR; Coles V; Hecht S; Radcliffe G; Sherman ME
    Cancer; 1998 Dec; 84(6):355-60. PubMed ID: 9915137
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of threshold values for determining the size of the fraction of steroid hormone receptor-positive tumor cells in paraffin-embedded breast carcinomas.
    Leers MP; Hoop JG; van Beers M; van Rodijnen N; Pannebakker M; Nap M
    Cytometry B Clin Cytom; 2005 Mar; 64(1):43-52. PubMed ID: 15668953
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays.
    Arihiro K; Umemura S; Kurosumi M; Moriya T; Oyama T; Yamashita H; Umekita Y; Komoike Y; Shimizu C; Fukushima H; Kajiwara H; Akiyama F
    Am J Clin Pathol; 2007 Mar; 127(3):356-65. PubMed ID: 17276950
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of the tumor associated proteases cathepsin D (CATH D) and urokinase-type plasminogen activator (uPA) in cytosols of human breast cancer patients.
    Liebert A; Quietzsch D; Beier L
    Anticancer Res; 1999; 19(4A):2571-6. PubMed ID: 10470197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group.
    Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS
    J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of estrogen receptor (ER) (beta)cx protein in ER(alpha)-positive breast cancer: specific correlation with progesterone receptor.
    Saji S; Omoto Y; Shimizu C; Warner M; Hayashi Y; Horiguchi S; Watanabe T; Hayashi S; Gustafsson JA; Toi M
    Cancer Res; 2002 Sep; 62(17):4849-53. PubMed ID: 12208729
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Immunohistochemical investigation of estrogen and progesterone receptors in breast tumors].
    Ellinidi VN; Anikseeva NV; Goncharova OA; Krasnozhon DA; Fedorov KA
    Vopr Onkol; 2004; 50(2):234-6. PubMed ID: 15176229
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.
    Cui X; Schiff R; Arpino G; Osborne CK; Lee AV
    J Clin Oncol; 2005 Oct; 23(30):7721-35. PubMed ID: 16234531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inter-laboratory quality control of estrogen and progesterone receptor assays in breast cancer tissue using lyophilised cytosols.
    Ryan ED; Clark AF; Mobbs BG; Ooi TC; Sutherland DJ; Tustanoff ER
    Clin Biochem; 1985 Feb; 18(1):20-6. PubMed ID: 3986988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Simultaneous immunohistochemical and biochemical hormone receptor assessment in breast cancer provides complementary prognostic information.
    Biesterfeld S; Schröder W; Steinhagen G; Koch R; Veuskens U; Schmitz FJ; Handt S; Böcking A
    Anticancer Res; 1997; 17(6D):4723-9. PubMed ID: 9494596
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.